Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Norethindrone Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | AR | P10275 | 4/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 4/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 0.70 |
| ▸ | ESR1 | P03372 | 3/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | MAOA | P21397 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norethindrone Acetate SCHEMBL14360522 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL11321479 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL14074495 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL14577826 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL1232662 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL16757740 | 0.96 | CYP3A4 (0.93) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL8038659 | 0.94 | CYP3A4 (0.89) | CYP3A4PGRABCB11CYP2C19AR | |
| Norethindrone Acetate SCHEMBL691854 | 0.94 | CYP3A4 (0.89) | CYP3A4PGRABCB11CYP2C19AR | |
| SCHEMBL11291553 | 0.92 | CYP3A4 (0.85) | CYP3A4PGRABCB11CYP2C19AR | |
| SCHEMBL9473282 | 0.91 | CYP3A4 (0.84) | CYP3A4PGRABCB11CYP2C19AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10406 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260117334-A1 | HOLLOW WIND TURBINE MAIN SHAFT AND PROFILING FORGING PROCESS AND USE THEREOF | Zenkung Heavy Industry (Jiangsu) Co., Ltd. (CN) | 2026-04-30 | — | — | US | claimed |
| EP-4440706-B1 | COMPOSITIONS FOR PROMOTING HAIR GROWTH | ESTETRA SRL (BE) | 2026-04-29 | — | — | EP | claimed |
| US-20260091041-A1 | Methods of Treating Heavy Menstrual Bleeding | ABBVIE INC (US) | 2026-04-02 | — | — | US | claimed |
| US-20260091036-A1 | Dosing Regimens for Elagolix | ABBVIE INC (US) | 2026-04-02 | — | — | US | claimed |
| CN-121586586-A | Process for preparing ophthalmic compositions of low solubility materials | 全福生物科技股份有限公司 | 2026-02-27 | — | — | CN | claimed |
| US-20260053736-A1 | LONG ACTING DRUG DELIVERY DEVICE AND ITS USE IN CONTRACEPTION | BAYER OY (FI) | 2026-02-26 | — | — | US | claimed |
| US-12551447-B2 | Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists | Sumitomo Pharma Co., Ltd. (JP) | 2026-02-17 | — | — | US | claimed |
| US-20260000613-A1 | INJECTABLE CONTROLLED-RELEASE FORMULATIONS OF PROGESTOGEN DRUGS | FORDOZ PHARMA CORP. (US) | 2026-01-01 | — | — | US | claimed |
| EP-4643858-A1 | METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF UTERINE DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-11-05 | — | — | EP | claimed |
| US-12390476-B2 | Multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen | Arkady, Rubin (US) | 2025-08-19 | — | — | US | claimed |
| US-4215691-A | Vaginal contraceptive system made from block copolymer | ALZA CORPORATION (US) | 1980-08-05 | — | — | US | claimed |
| US-4150108-A | STEROID ENTRAPPED IN COPOLYMER MATRIX FROM A BIS(DIHYDROPYRAN) | GRAHAM NEIL B | 1979-04-17 | — | — | US | claimed |
| US-4145416-A | ESTRADIOL AND ESTRIOL DERIVATIVES | SCHERING, A.G. (DE) | 1979-03-20 | — | — | US | claimed |
| US-4054651-A | Method of contraception | RICHARDSON-MERRELL INC. (US) | 1977-10-18 | — | — | US | claimed |
| US-4014988-A | Method for treating hypermenorrhea with uterine therapeutic system | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | claimed |
| US-3969502-A | 17-ALPHA ETHYNYLESTRADIOL AND NORGESTREL OR 17-ETHYNYL-19-NORTESTERONE ACETATE | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-07-13 | — | — | US | claimed |
| US-3957982-A | AN ESTROGEN AND A PROGESTOGEN | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-05-18 | — | — | US | claimed |
| US-3942641-A | Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens | SYNTEX CORPORATION (PM) | 1976-03-09 | — | — | US | claimed |
| US-3939264-A | 17ALPHA-ETHYNYL-ESTRADIOL AND NORGESTROL OR 17ALPHA-ETHYNYL-19-NORTESTERONE ACETATE | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-02-17 | — | — | US | claimed |
| US-3932635-A | Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens | SYNTEX CORPORATION (PM) | 1976-01-13 | — | — | US | claimed |